Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 2000 Dec;48(6):913-8. PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. First good evidence that the in vitro effects of muscarinic stimulation can be seen physiologically.

    View all comments by Edward Koo

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. AF102B (Cevimeline or Evoxac) Lowers CSF Aβ in Alzheimer Patients
  2. Cholinergic Systems and AD: Dark Clouds and Silver Linings